Medpace (MEDP) Stock Declines While Market Improves: Some Information for Investors

Medpace stock declined 2.84% on October 6, 2026, underperforming the broader market gains. The company is expected to report earnings on October 21 with projected EPS of $4.45 (up 15.28% YoY) and revenue of $708.75 million (up 7.4% YoY). However, the stock trades at a premium valuation with a Forward P/E of 35.38 versus the industry average of 16.59, and holds a Zacks Rank of #3 (Hold).